In the News
Dr Strauss performs first Agili-C cartilage repair on the East Coast
NEW YORK and KFAR SABA, Israel, Nov. 12, 2018 /PRNewswire/ -- CartiHeal, developer of Agili-C, a proprietary implant for the treatment of joint surface lesions, announced today the successful enrollment of the first patient in the Agili-C Investigational Device Exemption (IDE) pivotal study on the East Coast.
The surgery was performed by site Principal Investigator Eric J. Strauss, MD, an orthopedic surgeon at NYU Langone Health's Sports Medicine Center in New York City. NYU Langoprnewne is one of 15 U.S. sites in the new Food and Drug Administration (FDA) IDE trial and will enroll 20 patients with major knee cartilage injuries.